Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us

Registration           Hotel           Late Breaking Abstract Submission     Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
Poster Session OT1
Poster Session OT2
Poster Session OT3
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6

Program Schedule   >  Poster Sessions - Poster Session OT1

Poster Session OT1 
  Ongoing Clinical Trials 1: HER2
OT1-1-01 Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - The TRAIN-2 study
van Ramshorst MS, van Thienen JV, Stouthard JM, Rodenhuis S, Linn SC, Sonke GS. Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands.
OT1-1-02 A phase II randomized trial evaluating the effect of trastuzumab on disease free survival in early stage HER2-negative breast cancer patients with ERBB2- expressing bone marrow disseminated tumor cells
Aft R, Mudalagiriyappa C, Watson M, Pillai S, Fleming T, Trinkaus K, Pluard T. Washington University, St. Louis, MO.
OT1-1-03 A phase 3 randomized, double-blind trial comparing PF-05280014 + paclitaxel vs. trastuzumab + paclitaxel for treatment of HER2+ metastatic breast cancer patients
Ewesuedo R, Barker KB, Taylor CT, Jacobs I. Pfizer Inc., Cambridge, MA; Pfizer Inc., San Diego, CA; Pfizer Inc., New York, NY.
OT1-1-04 HER2 status of circulating tumor cells in HER2-positive metastatic breast cancer patients: A valuable biomarker in anti-HER2 therapy
Jiang Z, Li L, Liu Y, Wang T, Zhang S, Yuan Y, Bian L, Liu Q, Qi F. Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China; Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
OT1-1-05 Pernetta: A randomized phase II trial of pertuzumab + trastuzumab with or without chemotherapy, both followed by T-DM1 at progression, in patients with HER2-positive metastatic breast cancer - SAKK 22/10 / UNICANCER UC-0140/1207
Huober J, Weder P, Boven E, Oehlschlegel C, Mac Grogan G, Thuerlimann B, Li Q, Hawle H, Brauchli P, Ribi K, Gerard M-A, Lemonnier J, van Giesen J, Bonnefoi H. University of Ulm, Ulm, Germany; Breast Center, Cantonal Hospital, St. Gallen, Switzerland; VU University Medical Center, Amsterdam, Netherlands; Cantonal Hospital, St.Gallen, Switzerland; Institute Bergonie, Bordeaux, France; SAKK Coordinating Center, Bern, Switzerland; International Breast Cancer Study Group, Quality of Life Office, Bern, Switzerland; Unicancer Breast Cancer Group, Paris, France; BOOG Study Center, Amsterdam, Netherlands; Institute Bergonie, University Bordeaux, Bordeaux, France.
OT1-1-06 A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE)
Geyer CE, Loibl S, Mamounas EP, Untch M, Wolmark N, Huang C-S, Mano M, Zheng M, Smitt M, von Minckwitz G. National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; VCU Massey Cancer Center, Richmond, VA; German Breast Group (GBG), Neu-Isenburg, Germany; MD Anderson Cancer Center Orlando, Orlando, FL; HELIOS Hospital Berlin-Buch, Berlin, Germany; German Gynecological Oncology Working Group-Breast (AGO-B); Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA; National Taiwan University Hospital, Taipei, Taiwan; Cancer Institute of the State of São Paulo, São Paulo, Brazil; Genentech, Inc., South San Francisco, CA; University Women's Hospital, Frankfurt, Germany.
OT1-1-07 Phase II trial of paclitaxel combined with trastuzumab and pertuzumab as preoperative therapy for HER2 positive inflammatory breast cancer
Overmoyer BA, Regan M, Brugge J, Perou CM, Nakhlis F, Jennifer B, Heather J, Eren YD, Judith H-B, Winer E. Dana Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Brigham and Women's Hospital, Boston, MA; University of North Carolina at Chapel Hill, Chapel Hill, NC.
OT1-1-08 PERSEPHONE: Duration of trastuzumab with chemotherapy in women with HER-2+ve early breast cancer
Earl HM, Vallier A-L, Ogburn-Storey E, Cameron DA, Wardley AM, Miles D, Loi S, Hiller L, Higgins HB, Dunn JA. University of Cambridge, Cambridge, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Warwick Clinical Trials Unit, University of Warwick, Coventry, United Kingdom; Edinburgh University, Edinburgh, United Kingdom; The Christie Hospital, Manchester, United Kingdom; Mount Vernon Cancer Centre, London, United Kingdom.
OT1-1-09 ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy
Gradishar W, Wroblewski S, Huang Y, Harvey C, Franklin N, Johnston S. Northwestern University, Chicago, IL; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Stockley Park, Middlesex, United Kingdom; Royal Marsden NHS Foundation Trust & Institute of Cancer Research.
OT1-1-10 CirCe T-DM1 phase II trial: Assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with T-DM1
Bidard F-C, de Rycke Y, Asselain B, Dieras V, Lebofsky R, Pierga J-Y. Institut Curie, Paris, France.
OT1-1-11 DETECT III - A multicenter, randomized, phase III trial to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells
de Gregorio N, Schochter F, Melcher C, Hagenbeck C, Friedl TWP, Jäger B, Rack BK, Müller V, Fasching PA, Janni W, Fehm T. University of Ulm, Ulm, Germany; Heinrich Heine University, Ulm, Germany; Ludwig-Maximillians University, Munich, Germany; University Medical Center, Hamburg, Germany; Erlangen University Hospital, Erlangen, Germany.
OT1-1-12 SAFE-HEaRt: A pilot study assessing the cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function
Lynce F, Barac A, Tan MT, Nunes R, Herbolsheimer P, Isaacs C, Swain SM. MedStar Washington Hospital Center, Washington, DC; Georgetown University Medical Center, Washington, DC; MedStar Georgetown University Hospital, Washington, DC.
OT1-1-13 A phase II study with lead-in safety cohort of cabazitaxel plus lapatinib as therapy for patients with HER2-positive metastatic breast cancer (MBC) and intracranial metastases
Yardley DA, Hainsworth JD, Hamilton E, Hart LL, Shastry M, Finney L, Burris III HA. Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL.
  Ongoing Clinical Trials 1: Response Prediction
OT1-2-01 MINT I: Multi-institutional neo-adjuvant therapy, MammaPrint project I
Cox CE, Blumencranz P, Saez R, Wesolowski R, Stork-Sloots L, Gibson J, de Snoo F, Avisar E. University of South Florida, Tampa, FL; Morton Plant Hospital, Clearwater, FL; Plano Cancer Institute, Plano, TX; Ohio State University, Columbus, OH; Agendia NV, Amsterdam, Netherlands; Agendia Inc, Irvine, CA; Miller School of Medicine, University of Miami, Miami, FL.
OT1-2-02 PROMIS: Prospective study of MammaPrint in breast cancer patients with an intermediate recurrence score (PROMIS)
Soliman HH, Untch S, Stork-Sloots L. Moffitt Cancer Center, Tampa, FL; Agnedia Inc, Irvine, CA; Agendia NV, Amsterdam, Netherlands.
OT1-2-03 A prospective randomized phase II study to identify predictive biomarkers and mechanisms of resistance in patients with HER2-negative metastatic breast cancer treated with the combination of bevacizumab and paclitaxel
Foukakis T, Hartman J, Stone-Elander S, Jacobsson H, Bergh J. Karolinska Institutet, Stockholm, Sweden.
OT1-2-04 PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer
Vidal M, de la Peña L, Oliveira M, Cortés J, Llombart A, Prat A. Vall d'Hebron Institute of Oncology, Barcelona, Spain; Vall d'Hebron University Hospital, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  Ongoing Clinical Trials 1: Circulating Tumor Cells
OT1-3-01 Characterization of circulating tumor cells from subjects with metastatic breast cancer using the CTC-endocrine therapy index: The COMETI-P2-2012.0 trial
Paoletti C. University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
OT1-3-02 The treat CTC trial – A new approach targeting circulating tumor cells (CTC) in early breast cancer (EBC)
Rack B, Messina C, Litiere S, Dittrich C, Mavroudis D, Kong A, Sotiriou C, Pierga J-Y, Piccart M, Ignatiadis M. Ludwig-Maximilians-University, Munich, Germany; European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium; Kaiser Franz Josef Spital, Vienna, Austria; University General Hospital Heraklion, Heraklion, Greece; Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom; Institut Curie, Paris, France; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  Ongoing Clinical Trials 1: New Agents
OT1-4-01 Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC)
Isakoff SJ, Cruz C, Garber J, LLuch A, Perez Fidalgo JA, Tung N, Fernandez C, Kahatt C, Szyldergemajn S, Soto Matos-Pita A, Baselga J, Balmaña J. Massachusetts General Hospital, Boston; Hospital Vall d´Hebrón, Barcelona, Spain; Dana Farber Cancer Institute, Boston; Hospital Clínico de Valencia, Valencia, Spain; Beth Israel Deaconesse Medical Center, Boston; PharmaMar, Madrid, Spain; Memorial Sloan Kettering Cancer Center, NY.
OT1-4-02 Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC)
Matulonis UA, Wulf G, Cantley L, Mills G, Lasonde B, Atkinson T, Whalen C, Isakoff SJ, Westin S, Bell-McGuinn K, Winer E. Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Hospital, Boston, MA; Weill Cornell Medical College, New York, NY; MD Anderson Cancer Center, Houston, TX; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA.
OT1-4-03 Phase I study of erlotinib and metformin in triple negative breast cancer
Maurer M, Kalinsky K, Forman J, Jayasena R, Crew K, Hershman D. Columbia University, New York, NY.
OT1-4-04 A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer
Lluch-Hernández A, Ruiz Simon A, Huang C-S, Cortés Castán J, Ruiz-Borrego M, Telli M, Ismail-Khan R, Parton M, Tseng L-M, Chen S-C, Schmid P, Mayer I, Hurvitz S, García-Estévez L, Atienza R, Wu M, Cameron S, Beck JT, Bardia A. Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
OT1-4-05 Phase I dose-escalation study of oral administration of abexinostat (S 78454, PCI-24781) given with tamoxifen 20 mg in the treatment of patients with advanced breast cancer
Cortes J, Zucali PA, Santoro A, Munoz-Couselo E, Arnedos M, Cantero F, Kloos I, Depil S, Thomas E, Delaloge S. Vall d'Hebron University Hospital, Barcelona, Spain; Istituto Clinico Humanitas IRCCS, Rozzano, Italy; Institut Gustave Roussy, Villejuif, France; Institut de Recherches Internationales Servier, Suresnes, France.
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy